-
公开(公告)号：USD964569S1
公开(公告)日：2022-09-20
申请号：US29717686
申请日：2019-12-18
设计人： Sasha Bakhru , Bryan Laulicht , Stefan Zappe , Solomon Steiner
-
公开(公告)号：US10534006B2
公开(公告)日：2020-01-14
申请号：US15909677
申请日：2018-03-01
发明人： Sasha Bakhru , Bryan Laulicht , Stefan Zappe , Solomon Steiner
摘要： A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting/coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and/or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.
-
公开(公告)号：US20220155326A1
公开(公告)日：2022-05-19
申请号：US17590944
申请日：2022-02-02
发明人： Sasha Bakhru , Bryan Laulicht , Stefan Zappe , Solomon Steiner
摘要： A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting/coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and/or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.
-
公开(公告)号：US09910053B2
公开(公告)日：2018-03-06
申请号：US14849348
申请日：2015-09-09
申请人： Perosphere Inc.
发明人： Sasha Bakhru , Bryan Laulicht , Stefan Zappe , Solomon Steiner
CPC分类号： G01N33/86 , B01L3/502715 , B01L9/527 , B01L2300/0645 , B01L2300/0681 , B01L2300/0816 , B01L2300/1827 , G01N33/4905
摘要： A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting/coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and/or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.
-
公开(公告)号：US11852639B2
公开(公告)日：2023-12-26
申请号：US17590944
申请日：2022-02-02
发明人： Sasha Bakhru , Bryan Laulicht , Stefan Zappe , Solomon Steiner
CPC分类号： G01N33/86 , B01L3/502715 , B01L9/527 , G01N33/4905 , B01L2300/0645 , B01L2300/0681 , B01L2300/0816 , B01L2300/1827
摘要： A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting/coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and/or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.
-
公开(公告)号：US20230204606A1
公开(公告)日：2023-06-29
申请号：US17995930
申请日：2021-04-22
发明人： Xuan Jiang , Lirong Chen , Yongchen Wang , Dardan Osmani , Stefan Zappe , Randy Byrd , Sasha H. Bakhru
IPC分类号： G01N33/96
CPC分类号： G01N33/96 , G01N2333/81 , G01N2496/25 , G01N2496/05
摘要： The preparation and use of systems to provide surrogate whole blood controls using coagulation modifiers to simulate human whole blood in coagulation assays are disclosed.
-
公开(公告)号：US20240085440A1
公开(公告)日：2024-03-14
申请号：US18512673
申请日：2023-11-17
发明人： Sasha Bakhru , Bryan Laulicht , Stefan Zappe , Solomon Steiner
CPC分类号： G01N33/86 , B01L3/502715 , B01L9/527 , G01N33/4905 , B01L2300/0645 , B01L2300/0681 , B01L2300/0816 , B01L2300/1827
摘要： A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting/coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and/or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.
-
公开(公告)号：US11243219B2
公开(公告)日：2022-02-08
申请号：US16738863
申请日：2020-01-09
发明人： Sasha Bakhru , Bryan Laulicht , Stefan Zappe , Solomon Steiner
摘要： A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting/coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and/or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.
-
公开(公告)号：US10092641B2
公开(公告)日：2018-10-09
申请号：US15480564
申请日：2017-04-06
申请人： Perosphere Inc.
摘要： Methods and compositions for delivering antigens to the lymphatic system in doses that desensitize patients to future exposure to antigens have been developed. Rapid desensitization is achieved by introducing small quantities of antigen into the lymphatic system. In preferred embodiments, the compositions are administered to yield therapeutically effective levels of antigen within the lymph, where macrophages reside in the greatest concentration, by intradermal administration, using for example, microneedles or micro articles, oral administration, using for example, enteric coated capsules or tablets, or autologous transfusion. In some embodiments, the methods and compositions for delivering antigens orally achieve uptake by the Peyer's patches of the small intestines.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.013 秒)
